Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 5/20 | 0.73 |
| ▸ | MYC | P01106 | 4/20 | 0.73 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.73 |
| ▸ | MAX | P61244 | 3/20 | 0.73 |
| ▸ | CA2 | P00918 | 1/20 | 0.73 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.73 |
| ▸ | MAOA | P21397 | 1/20 | 0.69 |
| ▸ | CRHBP | P24387 | 2/20 | 0.68 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.68 |
| ▸ | CLK1 | P49759 | 1/20 | 0.68 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.68 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.68 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.68 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.68 |
| ▸ | IL1RN | P18510 | 1/20 | 0.68 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1125089 | 1.00 | NAT1 (0.73) | NAT1MYCCISD1MAXCA2 | |
| SCHEMBL12961168 | 1.00 | NAT1 (0.73) | NAT1MYCCISD1MAXCA2 | |
| SCHEMBL2555241 | 0.85 | PIM1 (0.72) | CISD1MAOANPC1RAB9A | |
| SCHEMBL1125015 | 0.85 | PIM1 (0.72) | CISD1MAOANPC1RAB9A | |
| SCHEMBL1125013 | 0.85 | PIM1 (0.72) | CISD1MAOANPC1RAB9A | |
| SCHEMBL8167436 | 0.85 | PIM1 (0.75) | NAT1MYCCISD1MAXCA2 | |
| SCHEMBL1249069 | 0.85 | NAT1 (1.00) | NAT1MYCCISD1MAXCA2 | |
| SCHEMBL20816059 | 0.85 | NAT1 (1.00) | NAT1MYCCISD1MAXCA2 | |
| SCHEMBL8167434 | 0.85 | PIM1 (0.75) | NAT1MYCCISD1MAXCA2 | |
| SCHEMBL8534665 | 0.85 | NAT1 (1.00) | NAT1MYCCISD1MAXCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | disclosed |
| US-7576215-B2 | Quinolines and pharmaceutical compositions thereof | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | NR1H2, NR1H3, SREBF1 | NAT1 221/4885MYC 3980/4885CISD1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.